GW Pharmaceuticals PLC
Companies
1993-2019
Filing Dates

211 filings

Newest first
10-Q
2019 Q2
GWPH GW Pharmaceuticals PLC
7 Aug 19
Quarterly report
8-K
GWPH GW Pharmaceuticals PLC
6 Aug 19
Results of Operations and Financial Condition
8-K
GWPH GW Pharmaceuticals PLC
26 Jul 19
Other Events
8-K
GWPH GW Pharmaceuticals PLC
13 Jun 19
Submission of Matters to a Vote of Security Holders
8-K
GWPH GW Pharmaceuticals PLC
13 Jun 19
Regulation FD Disclosure
10-Q
2019 Q1
GWPH GW Pharmaceuticals PLC
8 May 19
Quarterly report
8-K
GWPH GW Pharmaceuticals PLC
6 May 19
Results of Operations and Financial Condition
DEF 14A
GWPH GW Pharmaceuticals PLC
29 Apr 19
Definitive proxy
PRE 14A
GWPH GW Pharmaceuticals PLC
15 Apr 19
Preliminary proxy
8-K
GWPH GW Pharmaceuticals PLC
12 Apr 19
Departure of Directors or Certain Officers
8-K
GWPH GW Pharmaceuticals PLC
8 Apr 19
Completion of Acquisition or Disposition of Assets
8-K
GWPH GW Pharmaceuticals PLC
18 Mar 19
GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M
10-KT
2018 FY
GWPH GW Pharmaceuticals PLC
28 Feb 19
Filing
8-K
GWPH GW Pharmaceuticals PLC
26 Feb 19
Results of Operations and Financial Condition
S-3ASR
GWPH GW Pharmaceuticals PLC
18 Jan 19
Automatic shelf registration
8-K
GWPH GW Pharmaceuticals PLC
7 Jan 19
Regulation FD Disclosure
10-K
2018 FY
GWPH GW Pharmaceuticals PLC
29 Nov 18
Annual report
8-K
GWPH GW Pharmaceuticals PLC
27 Nov 18
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter and Year-End 2018 Financial Results and Operational Progress
8-K
GWPH GW Pharmaceuticals PLC
26 Nov 18
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome
8-K
GWPH GW Pharmaceuticals PLC
5 Oct 18
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs